Small biotech ALSP, Inc. is a privately held San Diego-based biotechnology firm with a focused small team, indicating a potential need for strategic partnerships, contract research support, or outsourced CRO services to scale research activities and accelerate drug discovery.

Neurodegenerative focus The company targets protease inhibitors for neurodegenerative diseases including traumatic brain injury and Alzheimer's, suggesting opportunities to sell research tools, assay development, screening libraries, and target validation services to broaden their pipeline.

Early-stage funding With revenue under one million and external funding of about 1.1 million, ALSP may seek deal-ready collaborations, grant support, or milestone-based partnerships with contract manufacturers, CROs, and biotech investors to extend capital efficiently.

Tech stack compatibility Their use of web and development technologies alongside standard research workflows implies openness to vendor solutions for data management, analytics, cloud-based collaboration, and secure R&D hosting to streamline operations.

Expansion potential Ambitions to expand beyond TBI and Alzheimer’s into Huntington’s, Parkinson’s, and MS indicate a broadening market opportunity; sales teams should position multi-disease protease screening capabilities and platform licensing to potential pharma partners.